Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extend… (NCT06101667) | Clinical Trial Compass
RecruitingNot Applicable
Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)
China224 participantsStarted 2023-11-16
Plain-language summary
The aim of this study is to assess the efficacy and safety of endovascular treatment versus medical management in patients with acute basilar artery occlusion with extended time window of 24-72 hours from onset.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age≥18 years
✓. Acute basilar artery occlusion confirmed by CTA, MRA, or DSA
✓. Pre-stroke mRS of 0-2
✓. NIHSS score ≥ 10 before randomization
✓. Time interval from symptom onset (or last known well) to randomization within 24-72 hours
✓. Diffusion-weighted imaging(DWI)-based pc-ASPECTS ≥ 6 and Pons-Midbrain Index (PMI) ≤3
✓. Time from completion of DWI imaging to randomization is ≤3 hours
✓. Each patient or their legal representative must provide written informed consent before enrolment
Exclusion criteria
✕. Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization
✕. Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging
✕. CT or MRI evidence of intracranial tumor (except small meningioma and cerebral aneurysm \< 3mm in diameter)
✕. Known or highly suspected chronic occlusion of basilar artery
✕. History of contraindication for contrast medium (except mild rash)
What they're measuring
1
Rate of modified Rankin scale 0-3 at 90 (±14) days after randomization